Shots:

• LYSA-LYSARC to conduct a P-II study to evaluate the safety and efficacy of valemetostat in six cohorts of patients with r/r B-cell lymphoma. The study will include ~140 patients at 22 sites in France and Belgium and is anticipated to be initiated in 2021
• The collaboration brings together Daiichi Sankyo’s science and the multidisciplinary expertise of the LYSA- LYSARC and the CALYM research consortium to conduct clinical and translational research that will build upon the ongoing P-I study of valemetostat in patients with r/r non-Hodgkin lymphoma
• Valemetostat (DS-3201) is an EZH1/2 dual inhibitor currently in clinical development for several hematologic cancers

 ­ Ref: Businesswire | Image: YouTube